More importantly, PARP inhibitors (PARPi) revolutionised the field of precision medicine in cancer when they were demonstrated to selectively kill tumours bearing germline mutations in the HR-associated genes Breast Cancer gene 1 and 2 (BRCA1/2) [7,8]. Here, BRCA1 is linked to neoplasm.